Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3413]

Clinical potential of trastuzumab biosimilar CTP6

Prof Francisco Esteva - NYU Langone Medical Center, New York, USA

Clinical potential of trastuzumab biosimilar CTP6 ( Prof Francisco Esteva - NYU Langone Medical Center, New York, USA )

ASCO 2017: Round up

Dr Bishal Gyawali - Nagoya University, Nagoya, Japan

ASCO 2017: Round up ( Dr Bishal Gyawali - Nagoya University, Nagoya, Japan )

Updates in melanoma: Treating BRAF and brain metastases

Prof Georgina Long - University of Sydney, Sydney, Australia

Updates in melanoma: Treating BRAF and brain metastases ( Prof Georgina Long - University of Sydney, Sydney, Australia )

Bendamustine for indolent lymphoma reduces relapse after 10 years

Dr Mathias Rummel - University of Giessen, Giessen, Germany

Bendamustine for indolent lymphoma reduces relapse after 10 years ( Dr Mathias Rummel - University of Giessen, Giessen, Germany )

ShortHER trastuzumab treatment of HER2 breast cancer: 9 weeks v 1 year

Prof Pierfranco Conte - Istituto Oncologico Veneto, Padova, Italy

ShortHER trastuzumab treatment of HER2 breast cancer: 9 weeks v 1 year ( Prof Pierfranco Conte - Istituto Oncologico Veneto, Padova, Italy )

T-VEC and checkpoint therapy for melanoma

Prof Robert Andtbacka - Huntsman Cancer Institute, Salt Lake City, USA

T-VEC and checkpoint therapy for melanoma ( Prof Robert Andtbacka - Huntsman Cancer Institute, Salt Lake City, USA )

Prevalence of homologous recombination deficiency among 53,000 tumour samples

Dr Arielle Heeke - Georgetown Lombardi Comprehensive Cancer Center, Washington...

Prevalence of homologous recombination deficiency among 53,000 tumour samples ( Dr Arielle Heeke - Georgetown Lombardi Comprehensive Cancer Center, Washington, USA )

Dacomitinib for EGFR positive lung cancer

Dr Tony Mok, The Chinese University of Hong Kong, Shatin, China

Dacomitinib for EGFR positive lung cancer ( Dr Tony Mok, The Chinese University of Hong Kong, Shatin, China )

Treating advanced melanoma with ipilimumab and HF10

Prof Robert Andtbacka - Huntsman Cancer Institute, Salt Lake City, USA

Treating advanced melanoma with ipilimumab and HF10 ( Prof Robert Andtbacka - Huntsman Cancer Institute, Salt Lake City, USA )

Ado-trastuzumab emtansine in patients with HER2 mutant lung cancers

Dr Bob Li - Memorial Sloan Kettering Cancer Center, New York, USA

Ado-trastuzumab emtansine in patients with HER2 mutant lung cancers ( Dr Bob Li - Memorial Sloan Kettering Cancer Center, New York, USA )

Alectinib eclipses crizotinib for ALK positive lung cancer

Dr Alice Shaw - Massachusetts General Hospital Cancer Center, Boston, USA

Alectinib eclipses crizotinib for ALK positive lung cancer ( Dr Alice Shaw - Massachusetts General Hospital Cancer Center, Boston, USA )

Adding a second HER2 targeted medicine may lower chance of invasive breast...

Dr Gunter von Minckwitz - German Breast Group, Neu-Isenburg, Germany

Adding a second HER2 targeted medicine may lower chance of invasive breast cancer ( Dr Gunter von Minckwitz - German Breast Group, Neu-Isenburg, Germany )

More from ecancer